Calico Life Sciences, backed by Alphabet, has entered into a deal valued up to $596 million with Mabwell Bioscience to acquire exclusive rights to investigational IL-11 targeting therapeutics, including the clinical-stage monoclonal antibody 9MW3811. This antibody is in phase 1 trials for idiopathic pulmonary fibrosis and has an active investigational new drug application with the U.S. FDA. The licensing agreement grants Calico rights outside greater China, aligning with its mission to develop interventions for aging-related diseases. Calico, founded by Alphabet and Arthur Levinson, is collaborating with industry players such as AbbVie and MIT’s Broad Institute to further longevity science.